Literature DB >> 22453015

The role of the PI3K-AKT pathway in melanoma.

Michael A Davies1.   

Abstract

The PI3K (phosphatidylinositol 3-kinase)-AKT pathway is one of the most important signaling networks in cancer. There is growing evidence that activation of this pathway plays a significant role in melanoma, frequently in the setting of concurrent activation of RAS-RAF-MEK-ERK signaling. This evidence includes the identification of genetic and epigenetic events that activate this pathway in melanoma cell lines and clinical specimens. In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance. The availability of many inhibitors against the PI3K-AKT pathway is rapidly leading to the development of trials that will ultimately determine its clinical significance in this disease. The rational development of such therapies will be facilitated by strategies that utilize the growing understanding of the complexity of the regulation and roles of this pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22453015     DOI: 10.1097/PPO.0b013e31824d448c

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  82 in total

1.  Transcriptome stability profiling using 5'-bromouridine IP chase (BRIC-seq) identifies novel and functional microRNA targets in human melanoma cells.

Authors:  Piyush Joshi; Tatsuya Seki; Shinobu Kitamura; Andrea Bergano; Bongyong Lee; Ranjan J Perera
Journal:  RNA Biol       Date:  2019-06-16       Impact factor: 4.652

2.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

3.  Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling.

Authors:  Deeba N Syed; Jean-Christopher Chamcheu; Mohammad Imran Khan; Mario Sechi; Rahul K Lall; Vaqar M Adhami; Hasan Mukhtar
Journal:  Biochem Pharmacol       Date:  2014-03-24       Impact factor: 5.858

4.  Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.

Authors:  Meng-Hua Dong; Qian Zhang; Yuan-Yuan Wang; Bai-Sui Zhou; Yu-Fei Sun; Qiang Fu
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

5.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

6.  WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Authors:  Jamie N Anastas; Rima M Kulikauskas; Tigist Tamir; Helen Rizos; Georgina V Long; Erika M von Euw; Pei-Tzu Yang; Hsiao-Wang Chen; Lauren Haydu; Rachel A Toroni; Olivia M Lucero; Andy J Chien; Randall T Moon
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

7.  Gambogenic acid induces cell growth inhibition, cell cycle arrest and metastasis inhibition in choroidal melanoma in a dose-dependent manner.

Authors:  Fenghua Li; Yansa Wang; Ying Yan
Journal:  Exp Ther Med       Date:  2017-03-22       Impact factor: 2.447

8.  Prepubertal Melanoma Arising within a Medium-Sized Congenital Melanocytic Nevus.

Authors:  Leah Lalor; Klaus Busam; Kara Shah
Journal:  Pediatr Dermatol       Date:  2016-08-30       Impact factor: 1.588

9.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

Review 10.  Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.

Authors:  Ethan B Butler; Yuhua Zhao; Cristina Muñoz-Pinedo; Jianrong Lu; Ming Tan
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.